An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01215123
First received: September 27, 2010
Last updated: August 4, 2014
Last verified: August 2014

September 27, 2010
August 4, 2014
January 2010
July 2012   (final data collection date for primary outcome measure)
To assess the median time of treatment duration of Avastin [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01215123 on ClinicalTrials.gov Archive Site
To assess the safety profile of Avastin [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Number of Participants with Adverse Events as a Measure of Safety [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study

This observational study will assess the median time of treatment duration and t he safety of Avastin (bevacizumab) as first line treatment in patients with meta static breast cancer. Data will be collected for approximately 24 months.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Breast cancer patients with first line treatment with Avastin

Breast Cancer
Not Provided
Cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin

Exclusion Criteria:

  • Patients not willing or unable to signed written consent form
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Argentina
 
NCT01215123
ML25100
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP